Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer.

Amorim BJ, Prabhu V, Marco SS, Gervais D, Palmer WE, Heidari P, Vangel M, Saylor PJ, Catalano OA.

Eur J Nucl Med Mol Imaging. 2019 Sep 6. doi: 10.1007/s00259-019-04506-1. [Epub ahead of print]

PMID:
31492992
2.

Case 14-2019: A 44-Year-Old Man with Neck Pain and Swelling.

Saylor PJ, Dudzinski DM, Mendoza DP, Glomski K.

N Engl J Med. 2019 May 9;380(19):1854-1863. doi: 10.1056/NEJMcpc1900421. No abstract available.

PMID:
31067377
3.

Predicting 90-Day and 1-Year Mortality in Spinal Metastatic Disease: Development and Internal Validation.

Karhade AV, Thio QCBS, Ogink PT, Bono CM, Ferrone ML, Oh KS, Saylor PJ, Schoenfeld AJ, Shin JH, Harris MB, Schwab JH.

Neurosurgery. 2019 Oct 1;85(4):E671-E681. doi: 10.1093/neuros/nyz070.

PMID:
30869143
4.

Development of Machine Learning Algorithms for Prediction of 30-Day Mortality After Surgery for Spinal Metastasis.

Karhade AV, Thio QCBS, Ogink PT, Shah AA, Bono CM, Oh KS, Saylor PJ, Schoenfeld AJ, Shin JH, Harris MB, Schwab JH.

Neurosurgery. 2019 Jul 1;85(1):E83-E91. doi: 10.1093/neuros/nyy469.

PMID:
30476188
5.

Case 36-2018: A 29-Year-Old Man with an Incidentally Discovered Renal Mass.

Dahl DM, Simeone JF, Iliopoulos O, Saylor PJ, Wu CL.

N Engl J Med. 2018 Nov 22;379(21):2064-2072. doi: 10.1056/NEJMcpc1802832. No abstract available.

PMID:
30462933
6.

Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.

Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU.

J Clin Oncol. 2019 Jan 1;37(1):44-51. doi: 10.1200/JCO.18.00537. Epub 2018 Nov 15.

7.

Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.

Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA.

Eur Urol. 2017 Jun;71(6):952-960. doi: 10.1016/j.eururo.2016.12.020. Epub 2017 Jan 9.

PMID:
28081860
8.

Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.

Saylor PJ, Lee RJ, Arora KS, Deshpande V, Hu R, Olivier K, Meneely E, Rivera MN, Ting DT, Wu CL, Miyamoto DT.

Clin Cancer Res. 2017 Jan 15;23(2):363-369. doi: 10.1158/1078-0432.CCR-16-0237. Epub 2016 Jul 20.

9.

Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations.

Singh H, Liu Y, Xiao X, Lin L, Kim J, Van Hummelen P, Wu CL, Bass AJ, Saylor PJ.

Oncotarget. 2016 May 17;7(20):29211-5. doi: 10.18632/oncotarget.8640.

10.

CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 38-2015. A 21-Year-Old Man with Fatigue and Weight Loss.

Pallais JC, McInnis M, Saylor PJ, Wu RI.

N Engl J Med. 2015 Dec 10;373(24):2358-69. doi: 10.1056/NEJMcpc1506821. No abstract available.

PMID:
26650156
11.

Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

Ryan CJ, Saylor PJ, Everly JJ, Sartor O.

Oncologist. 2014 Oct;19(10):1012-8. doi: 10.1634/theoncologist.2013-0472. Epub 2014 Sep 17. Review.

12.

Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.

Saylor PJ.

Asian J Androl. 2014 May-Jun;16(3):341-7. doi: 10.4103/1008-682X.122591. Review.

13.

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.

Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR.

Clin Cancer Res. 2013 Jun 1;19(11):3088-94. doi: 10.1158/1078-0432.CCR-13-0319. Epub 2013 Apr 3.

14.

Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer.

Saylor PJ, Smith MR, O'Malley AJ, Keating NL.

Eur Urol. 2014 Mar;65(3):642-9. doi: 10.1016/j.eururo.2013.02.003. Epub 2013 Feb 12.

15.

Prostate cancer: The androgen receptor remains front and centre.

Saylor PJ.

Nat Rev Clin Oncol. 2013 Mar;10(3):126-8. doi: 10.1038/nrclinonc.2013.14. Epub 2013 Feb 5. Review. No abstract available.

PMID:
23381000
16.

Metabolic complications of androgen deprivation therapy for prostate cancer.

Saylor PJ, Smith MR.

J Urol. 2013 Jan;189(1 Suppl):S34-42; discussion S43-4. doi: 10.1016/j.juro.2012.11.017. Review.

PMID:
23234628
17.

New and emerging therapies for bone metastases in genitourinary cancers.

Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K.

Eur Urol. 2013 Feb;63(2):309-20. doi: 10.1016/j.eururo.2012.10.007. Epub 2012 Nov 23. Review.

18.

Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.

Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD.

J Nucl Med. 2012 Nov;53(11):1670-5. doi: 10.2967/jnumed.112.105007. Epub 2012 Sep 14.

19.

Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer.

Saylor PJ, Karoly ED, Smith MR.

Clin Cancer Res. 2012 Jul 1;18(13):3677-85. doi: 10.1158/1078-0432.CCR-11-3209. Epub 2012 May 15.

20.

Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.

Saylor PJ, Escudier B, Michaelson MD.

Clin Genitourin Cancer. 2012 Jun;10(2):77-83. doi: 10.1016/j.clgc.2012.01.010. Epub 2012 Feb 28. Review.

PMID:
22382009
21.

Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.

Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG.

Oncologist. 2012;17(2):212-9. doi: 10.1634/theoncologist.2011-0321. Epub 2012 Feb 2.

22.

Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?

Saylor PJ, Michaelson MD.

Oncologist. 2012;17(2):288-90. doi: 10.1634/theoncologist.2011-0433. Epub 2012 Jan 20.

23.

Emerging therapies to prevent skeletal morbidity in men with prostate cancer.

Saylor PJ, Lee RJ, Smith MR.

J Clin Oncol. 2011 Sep 20;29(27):3705-14. doi: 10.1200/JCO.2010.34.4994. Epub 2011 Aug 22. Review.

24.

Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer.

Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR.

J Urol. 2011 Aug;186(2):482-6. doi: 10.1016/j.juro.2011.03.111. Epub 2011 Jun 15.

25.

Prostate cancer imaging: what surgeons, radiation oncologists, and medical oncologists want to know.

Tabatabaei S, Saylor PJ, Coen J, Dahl DM.

AJR Am J Roentgenol. 2011 Jun;196(6):1263-6. doi: 10.2214/AJR.10.6263. Review.

PMID:
21606287
26.

Targeted therapies: denosumab--a new option for solid tumors metastatic to bone.

Saylor PJ.

Nat Rev Clin Oncol. 2011 Jun;8(6):322-4. doi: 10.1038/nrclinonc.2011.70. Epub 2011 May 10. No abstract available.

PMID:
21556026
27.

Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.

Saylor PJ, Keating NL, Freedland SJ, Smith MR.

Drugs. 2011 Feb 12;71(3):255-61. doi: 10.2165/11588930-000000000-00000. No abstract available.

28.

Contemporary therapeutic approaches targeting bone complications in prostate cancer.

Lee RJ, Saylor PJ, Smith MR.

Clin Genitourin Cancer. 2010 Dec 1;8(1):29-36. doi: 10.3816/CGC.2010.n.005. Review.

29.

Re: Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy. Editorial comment.

Saylor PJ.

J Urol. 2010 Sep;184(3):923; author reply 924. doi: 10.1016/j.juro.2010.04.088. No abstract available.

PMID:
20643451
30.

Treatment and prevention of bone complications from prostate cancer.

Lee RJ, Saylor PJ, Smith MR.

Bone. 2011 Jan;48(1):88-95. doi: 10.1016/j.bone.2010.05.038. Epub 2010 May 31. Review.

31.

Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.

Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR.

J Urol. 2010 Jun;183(6):2200-5. doi: 10.1016/j.juro.2010.02.022.

32.

Prostate-cancer-associated hypercoagulability: do we need to worry about androgen deprivation?

Saylor PJ, Fogerty AE.

Lancet Oncol. 2010 May;11(5):406-7. doi: 10.1016/S1470-2045(10)70063-2. Epub 2010 Apr 13. No abstract available.

PMID:
20395175
33.

Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.

Saylor PJ, Smith MR.

J Natl Compr Canc Netw. 2010 Feb;8(2):211-23. Erratum in: J Natl Compr Canc Netw. 2010 Mar;8(3):xlv.

34.

Bone health and prostate cancer.

Saylor PJ, Smith MR.

Prostate Cancer Prostatic Dis. 2010 Mar;13(1):20-7. doi: 10.1038/pcan.2009.50. Epub 2009 Nov 10. Review.

35.

Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.

Saylor PJ, Keating NL, Smith MR.

J Gen Intern Med. 2009 Nov;24 Suppl 2:S389-94. doi: 10.1007/s11606-009-0968-y. Review.

36.

Prostate cancer: How can we improve the health of men who receive ADT?

Saylor PJ, Smith MR.

Nat Rev Urol. 2009 Oct;6(10):529-31. doi: 10.1038/nrurol.2009.195. No abstract available.

37.

New treatments for renal cell carcinoma: targeted therapies.

Saylor PJ, Michaelson MD.

J Natl Compr Canc Netw. 2009 Jun;7(6):645-56. Review.

PMID:
19555586
38.

Metabolic complications of androgen deprivation therapy for prostate cancer.

Saylor PJ, Smith MR.

J Urol. 2009 May;181(5):1998-2006; discussion 2007-8. doi: 10.1016/j.juro.2009.01.047. Epub 2009 Mar 14. Review.

39.

Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.

Saylor PJ, Reid TR.

J Clin Oncol. 2007 Aug 10;25(23):3544-6. No abstract available.

PMID:
17687160

Supplemental Content

Loading ...
Support Center